Capecitabine/Cyclophosphamide - Sanofi

Drug Profile

Capecitabine/Cyclophosphamide - Sanofi

Alternative Names: Cyclophosphamide/Capecitabine - Sanofi; SAR-439281

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi
  • Class Antineoplastics; Carbamates; Cyclophosphamides; Myeloablative agonists; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Alkylating agents; Antimetabolites; DNA cross linking agents; DNA synthesis inhibitors; Immunomodulators; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 06 Nov 2017 Sanofi completes a phase II trial in Breast cancer (Metastatic disease, Second-line therapy or greater) in India (PO) (NCT02664103)
  • 05 Feb 2016 Preclinical trials in Breast cancer in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top